Home Knowledge Hub Nemera expands diabetes device portfolio and prepares for the future Nemera expands diabetes device portfolio and prepares for the future 05/06/2021 Share this article: Facebook Twitter LinkedIn
2023 2024 ESG Our 2023 ESG report is published! 05/06/2024 Read our 2023 ESG report to know more where we stand today on sustainability, our strategic priorities and objectives Continue Reading
2023 ESG The Gender Equality Index at Nemera – Year 2023 28/02/2024 The Index, is calculated from 4 to 5 indicators depending on whether the company has less or more than 250 employees and takes into account Continue Reading
2024 Cristalia products with Nemera’s reusable pen injector commercialized in Brazil. 30/01/2024 Cristalia’s human growth hormone will be administered with CRISPEN®. Approved by ANVISA1, CRISPEN® is part of Nemera’s state-of-the-art pen injector platform PENDURA AD. Continue Reading